Home/ Stocks/ VCEL

Vericel Corporation

VCEL XNAS

$33.46 -1.49 (-4.24%) ▼ 15-min delayed

Open

$34.74

High

$34.74

Low

$31.86

Volume

1.54M

Market Cap

$1.71B

About Vericel Corporation

Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 398 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$68.42M	$-6,302,000	$-0.12
FY 2025	$276.26M	$16.52M	$0.33
Q3 2025	$67.50M	$5.07M	$0.10
Q2 2025	$63.24M	$-553,000	$-0.01

Related Market News

No specific coverage for VCEL yet. Check out our latest market news or earnings calendar.

Get VCEL Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Vericel Corporation.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.